Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 2
6(100.0%)
6Total
Phase 2(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07459647Phase 2Recruiting

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

Role: lead

NCT07459660Phase 2Recruiting

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

Role: lead

NCT05889273Phase 2Enrolling By Invitation

ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)

Role: lead

NCT07038876Phase 2Recruiting

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Role: lead

NCT06887192Phase 2Recruiting

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

Role: lead

NCT05081245Phase 2Active Not Recruiting

ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

Role: lead

All 6 trials loaded